Lilly oral GLP-1 shows cardiovascular safety in diabetes study
Lilly said its oral GLP-1, orforglipron, demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study.
Lilly said its oral GLP-1, orforglipron, demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study.